Over the past six months, Regeneron’s stock price fell to $587.01. Shareholders have lost 11.7% of their capital, which is ...

Regeneron's Phase 3 trials for cat and birch allergies show significant symptom relief and strong safety results, paving the ...

Below is Validea's guru fundamental report for REGENERON PHARMACEUTICALS INC (REGN). Of the 22 guru strategies we follow, REGN rates highest using our Value Investor model based on the published ...

Regeneron Pharmaceuticals, Inc. shares have lost >50% of their value over the past 12 months. Regeneron remains a powerhouse pharma however, despite threats to its key drug Eylea from generics and ...

Regeneron acquired a promising weight management asset that could become lucrative. This investigational medicine helps beef up the biotech's already exciting pipeline. There are also several other ...

On this episode of Stock Movers: - Ulta Beauty (ULTA) shares leap as much as 16% on Friday, the most intraday since November 2020, after the cosmetics retailer boosted its earnings per share forecast ...

Regeneron Pharmaceuticals stock slumped on Friday after two late-stage trials for an experimental drug co-developed with Sanofi only partially met goals ...

Shares of Regeneron Pharmaceuticals Inc. REGN slipped 4.06% to $634.14 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising ...